Multidrug-resistant Cancer Treatment Development

Despite its shortcomings, chemotherapy remains the first line of treatment against most cancers. But far too often it fails when a targeted tumor develops drug resistance. As resistance progresses, patients have fewer and fewer treatment options, and their cancer spreads. Over 90% of chemotherapy patient deaths are a result of the development of multidrug resistance.

Verseon is developing novel chemotherapy agents whose efficacy is unimpaired by the development of resistance to other drugs. We are determined to prevent deaths from multidrug-resistant cancers.